Navigation Links
Newer Sedative Might Help Patients on Ventilators
Date:12/11/2007

Preliminary study finds dexmedetomidine caused less delirium,,,,

TUESDAY, Dec. 11 (HealthDay News) -- Doctors routinely use sedatives on patients who are hooked up to mechanical ventilators in intensive care units, but some experts worry that too much sedation might slow down recovery and leave patients in an unnecessary fog.

Now, researchers report that by substituting a newer medication, dexmedetomidine (Precedex), for the more commonly used lorazepam (Ativan), doctors could reduce the amount of time patients experience delirium and coma. They also found a reduction in the length of time on mechanical ventilation and an improvement in survival, though these differences didn't reach the level of statistical significance.

"By changing the way we give medications, we may be able to improve outcomes," said study author Dr. Pratik Pandharipande, from the anesthesiology and critical care department at Vanderbilt University Medical Center in Nashville, Tenn. His report is published in the Dec. 12 issue of the Journal of the American Medical Association.

"By incorporating this sedative, patients had four more days alive without delirium or coma. They also had greater time off the mechanical ventilator and had shorter ICU stays. And, there was an important trend toward decreased mortality, about a 10 percent reduction in mortality," he said.

However, not everyone is convinced that the newer sedative is a significant improvement.

"This study reminds me of the importance in minimizing sedation. The principles of this study make sense to me, but the study is flawed. They started using 10 milligrams per hour of lorazepam, and it's a dose we don't use. It's a rarity to use a dose that high," said Dr. Kevin Grady, interim chief medical officer for St. John's Health System and director of pulmonary and critical care at St. John Hospital and Medical Center in Detroit. Grady said a more standard dose of lorazepam is 2 to 4 milligrams per hour.

"This just doesn't prove to me that dexmedetomidine is better than lorazepam," added Grady.

The current study included 106 people hospitalized in the ICU and on mechanical ventilators. They were randomly assigned to receive sedation either with dexmedetomidine or with lorazepam. The sedation period varied but lasted as long as 120 hours.

While the manufacturer of dexmedetomidine, Hospira, provided an unrestricted grant and the study medication to the researchers, the company had no input in the study's design, conduct or analysis, according to the authors.

The researchers found that sedation with dexmedetomidine reduced the number of days that patients experienced delirium or coma by an average of four days. The prevalence of coma was 92 percent for those on lorazepam and 63 percent for those on dexmedetomidine.

The 28-day mortality rate was 27 percent for the lorazepam group versus 17 percent for those on dexmedetomidine.

According to Pandharipande, although the initial cost of dexmedetomidine might be higher than that of lorazepam, the improved outcomes offset that cost.

Because the study size was small, Pandharipande said more research needs to be done to confirm these findings, but that this study offered "proof of concept."

"We do have an alternate sedation strategy to reduce the burden of brain dysfunction," said Pandharipande.

Grady said there are certain patients who may benefit more from the use of dexmedetomidine, such as those going through alcohol withdrawal. But, until further studies are done, Grady added, "I'm hard-pressed to think it's worth the expense. This drug costs twice as much as lorazepam."

More information

Read more about lorazepam and its potential side effects at the U.S. National Library of Medicine.



SOURCES: Pratik Pandharipande, M.D., department of anesthesiology and critical care, Vanderbilt University Medical Center, Nashville, Tenn.; Kevin Grady, M.D., director, pulmonary and critical care, St. John Hospital and Medical Center, and interim chief medical officer, St. John's Health System; Dec. 12, 2007, Journal of the American Medical Association


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Newer antidepressants led to less, not more, teen suicides
2. Newer Antibiotic Speeds TB Healing
3. Newer radiation treatment easier for some throat cancer patients
4. Newer Anticlotting Drug Safe, Effective for Heart Surgeries
5. Fish Oil Might Help Relieve MS
6. HIV Drug Might Fight Cancer
7. High and mighty: first common height gene identified by researchers behind obesity gene finding
8. Vitamin C Plus Fat Might Spur Cancer
9. Mathematics might save you a trip to the ER
10. Veggies Might Ward Off Age-Linked Vision Woes
11. Rating your pain from 0 to 10 might not help your doctor
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Newer Sedative Might Help Patients on Ventilators
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC (SCP) ... obtaining investment capital for emerging technology companies. SCP has delivered investment events ... in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, ... organization dedicated to helping service members that have been wounded in battle and their ...
(Date:6/24/2016)... Gilbert, Arizona (PRWEB) , ... June 24, 2016 ... ... Gilbert-based practice, is supporting the upcoming 2016 Miss Arizona pageant as its official ... primarily serves Scottsdale, Tempe, Mesa, and Chandler, Arizona. , Dr. Olson says ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
Breaking Medicine Technology: